MaaT Pharma is the leading microbiome company in oncology.
The Company owns in-house cGMP manufacturing capacities and specializes in developing Microbiome Ecosystem Therapies dedicated to enhancing the survival of cancer patients, with a focus on treating and preventing complications in blood cancers and improving treatments in immuno-oncology.

MaaT013, a pooled-donor microbiome ecosystem therapy, is a non-immunosuppressive treatment dedicated to treat acute GvHD.
As of today, MaaT013 has been administered to more than 200 patients.
A Phase 3 trial is currently ongoing with ORR results expected in mid-2024.
The Company has an open-IND granted by the U.S. FDA and has engaged active discussions with prominent US clinicians in the field of stem cell transplantation to explore the most efficient path forward to introduce MaaT013 to patients in the United States.
MaaT013 has been awarded Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA).

MaaT033, a donor-derived, high-richness, high-diversity oral Microbiome Ecosystem TherapyTM containing is currently ongoing Phase 2 as an adjunctive therapy to improve overall survival in patients receiving HSCT and other cellular therapies.
MaaT033 has been granted Orphan Drug Designation by the European Medicines Agency (EMA) in August 2023.

– Therapeutic areas: Oncology, Hemato-Oncology: acute Graft-versus-Host Disease (aGvHD), allogenic hematopoietic stem cell transplantation; Immuno-oncology: metastatic melanoma; Neurodegenerative diseases : Amyotrophic lateral sclerosis (ALS).

– Based in: Lyon (FRANCE)

– Employees: 51-200

– Created in: 2014